APA (7th ed.) Citation

S, T., C, M., A, K., & AM, D. (2026). Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine. Pharmaceutical medicine, 40(4), 275. https://doi.org/10.1007/s40290-026-00611-3

Chicago Style (17th ed.) Citation

S, Tomlin, Mühlhausen C, Krendyukov A, and Das AM. "Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine." Pharmaceutical Medicine 40, no. 4 (2026): 275. https://doi.org/10.1007/s40290-026-00611-3.

MLA (9th ed.) Citation

S, Tomlin, et al. "Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine." Pharmaceutical Medicine, vol. 40, no. 4, 2026, p. 275, https://doi.org/10.1007/s40290-026-00611-3.